NOVADISCOVERY, a pioneer in in silico clinical trials, today announced the strengthening of its team with the nomination of its new Chief Scientific Officer, David duVerle, and the appointment of Prof. Marc Hommel as VP of Medicine.
Live
Stay informed about what's happening at Nova#drugR&D #insilicomedicine #systemsbiology #biomodeling #machinelearning
Novadiscovery prémodélise les essais cliniques pour gagner en efficacité – Les Echos
Jusqu’ici, la recherche pharmaceutique était in vitro ou in vivo. Il existe un nouveau modèle, in silico , dans le monde immatériel de l’informatique…
La recherche in silico en plein développement – Le Quotidien du Médecin
La recherche in silico reste toutefois très déterministe. « Il faut définir la question posée et ne simuler que les systèmes et les mécanismes qui permettent d’y répondre », ajoute le Pr Jean-Pierre Boissel, Novadiscovery.
Quand les essais cliniques plongent dans le virtuel – Les Echos
Beaucoup d’arguments militent en faveur du in silico en complément et en renforcement mais non en remplacement des recherches in vitro et in vivo.
ICSB 2018
Two posters presented by Novadiscovery’s team at ICSB 2018, October 28 – November 1, 2018.
#realICSB2018
Totem HealthTech organisé par BpifranceHub : Dans quelle mesure intégrer l’IA dans le parcours de soin ?
François-Henri BOISSEL est invité lors du Totem HealthTech de BpifranceHub aux côtés de @therapixel et du Dr Jean Sébastien Hulot
PAGE 2018 Meeting: An in silico model of Hepatitis B virus predicts patients response to ENYO PHARMA’s drug candidate EYP001
NOVADISCOVERY presents first results from the in silico component of the exploratory clinical program initiated by ENYO Pharma on EYP001, a non-bile acid FXR receptor agonist currently in phase 1b trial for the treatment of chronic Hepatitis B.
NOVADISCOVERY and ENYO Pharma sign a collaboration agreement
to accelerate the clinical development of drug candidate EYP001.
October 2, 2017
FDA News: Congress Pushes for In Silico Trial Modeling
Watershed moment for in silico clinical trials as the FDA receives formal congressional requirement to apply in silico for the evaluation of new drugs.
Novadiscovery inaugurates its new premises
In the presence of Mme Françoise Grossetête, Member of the European Parliament & Dr Adriano Henney, Secretary General of Avicenna Alliance.
Avicenna Alliance proclaims victory in EMA regulation
The Avicenna Alliance has claimed a major victory in the revised EMA Regulation with the introduction of new text supporting modeling and simulation and predictive medicine in medicinal product development
Release of the Avicenna Alliance roadmap
The Avicenna Alliance, which Nova is a founding member of, releases its roadmap “in silico Clinical Trials: How Computer Simulation will Transform the Biomedical Industry”. This roadmap has been approved by the European Commission.
H2020 research grant for the RESSTORE project
Novadiscovery secures an H2020 research grant for the RESSTORE project aimed at the clinical evaluation of a cell-based regenerative therapy in acute ischemic stroke
Award at the BIOVISION Catalyzer competition
Novadiscovery is delighted to announce an award at the BIOVISION Catalyzer competition for its GitHealth open science platform.
Position paper in Nature’s CPT: Bridging Systems Medicine and Patient Needs
A publication by Jean-Pierre Boissel, Charles Auffray, Denis Noble, Lee Hood, François-Henry Boissel in CPT Pharmacometrics Systems Pharmacololgy, March 2015 : Bridging systems medicine and patient needs
NOVADISCOVERY is proud to announce the launch of project PREDICTIV
A personalized medicine project centered on breast, colorectal and lung cancers.
NOVADISCOVERY to represent the SysCLAD consortium
at the 20th-anniversary edition of the prestigious International Congress on Lung Transplantation, in Paris.